A Natural Sugar Could Become the First Treatment for Limb-Girdle Muscular Dystrophy 2I/R9 on November 27th

What if the first treatment for any kind of limb-girdle muscular dystrophy turns out to be a sugar the body already makes? The FDA plans to decide by November 27, 2026 whether to approve BBP-418, a powder of a natural sugar alcohol called ribitol, for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). No treatment is approved for LGMD2I/R9 today. If the FDA says yes, BridgeBio says it would be the first for this form of the disease and possibly the first for any form of LGMD.

What LGMD2I/R9 Is, and Why the FKRP Gene Matters

Every time a muscle tightens, its cells pull against the tissue around them. A protein called alpha-dystroglycan anchors each cell so it does not tear. The anchor only holds when it carries a coat of sugar chains, and an enzyme called FKRP adds one of the links in that coat. In LGMD2I/R9, both copies of the FKRP gene carry a change that leaves the enzyme only partly working. The coat comes out thin, and muscle cells are damaged a little more with each use.

The weakness usually starts in the hips and thighs, which makes climbing stairs and getting up from a chair hard, and later spreads to the shoulders. Breathing muscles and the heart can be affected too. In a group of 56 people followed at the University of Iowa, 45% had heart muscle disease, called cardiomyopathy (Libell et al., Muscle Nerve, 2020). How fast the disease moves depends a great deal on which FKRP changes a person has.

• The most common change, called L276I or c.826C>A, usually brings symptoms in late childhood when a person has 2 copies of it. By adulthood, BridgeBio says, about 25% lose the ability to walk on their own, 10% need help breathing and 30% develop cardiomyopathy.
• Other FKRP combinations usually start earlier and move faster, with loss of walking by age 20 and heart involvement in about 60%, according to BridgeBio.
• Across 97 people in the Iowa natural history study, half had lost the ability to walk by age 46, and the youngest was 9 (Miller et al., Annals of Clinical and Translational Neurology, 2026).

LGMD2I/R9 is rare almost everywhere. Norway has the highest rate reported, nearly 3 people in every 100,000, from 153 people with a confirmed diagnosis (Jensen et al., Neuromuscular Disorders, 2023).

Ribitol is the raw material the FKRP enzyme works with. The body turns it into CDP-ribitol, the exact building block FKRP attaches to alpha-dystroglycan. In LGMD2I/R9 the enzyme still works a little, and BBP-418 is designed to flood it with building blocks so that it can finish more of the sugar coat. Think of a slow assembly line that keeps up better when it never runs short of parts.

In the trial, BBP-418 came as granules in packets, mixed with water and taken twice a day. The dose was 9 grams twice a day for people over 30 and up to 50 kg, and 12 grams twice a day above 50 kg, according to BridgeBio's study in healthy adults (Gretler et al., Clinical Pharmacology in Drug Development, 2026). That study found ribitol could be taken with or without food. The dose an FDA label would set is not known yet.

What the FORTIFY Trial Showed for BBP-418

FORTIFY enrolled 112 people aged 12 to 60, 74 assigned by chance to BBP-418 and 38 to placebo, a look-alike powder with no drug, at 21 sites, 13 of them in the United States (ClinicalTrials.gov NCT05775848). Neither the participants nor their doctors knew who got which. The trial runs for 3 years, and the results so far come from a planned check at 12 months, which BridgeBio says met every main and secondary goal it was testing.

BridgeBio is asking for traditional approval, the standard kind, based on those 12-month results rather than on a lab marker alone. The FDA gave the application priority review and set November 27, 2026 as its target date, and BridgeBio said the FDA was not planning an advisory committee meeting (BridgeBio, May 2026). The company also reported that the effect looked similar across age groups, across FKRP genotypes and in people with weaker or stronger breathing at the start.

The Heart Finding, and Why It Is Early

On October 5, 2026, BridgeBio presented a closer look at the heart at the World Muscle Society congress. At the start of the trial, 25 of 109 participants had a raised level of high-sensitivity troponin I, a blood sign of heart muscle injury, and 18 of 105 had an ejection fraction, the share of blood the heart pumps out with each beat, below 50%. By month 12, every evaluable person on BBP-418 whose troponin had been raised was back in the normal range, compared with 40% on placebo. Heart pumping was stable or better in 54% of people on BBP-418 and 25% on placebo.

BridgeBio describes these heart results as exploratory, outside the trial's planned statistical tests, and based on small groups. They point in a hopeful direction for a disease where the heart often decides the long-term outlook, and the full 3-year results will show whether they hold.

BBP-418 Side Effects in the Trial

Side effects were about as common on BBP-418 as on placebo, according to the results BridgeBio presented in March 2026. Serious side effects happened in 5.4% of people on BBP-418 and 7.9% on placebo. None of the serious side effects was judged to be caused by the drug, and no one died. The most common side effects on BBP-418 were these, with placebo rates in parentheses:

• Diarrhea in 39 in 100 people (53 in 100 on placebo), all of it mild to moderate
• Pain after a study procedure in 20 in 100 (11 in 100)
• Falls in 19 in 100 (26 in 100)
• Nausea in 16 in 100 (8 in 100)
• Joint pain in 15 in 100 (11 in 100)
• Headache in 11 in 100 (13 in 100)

BridgeBio reported no pattern of liver, kidney, heart or blood problems in lab tests, and no meaningful changes in heart tracings or heart ultrasounds. A dedicated study in healthy adults found no meaningful change in the heart's electrical rhythm at doses up to 21 grams (Gretler et al., 2026).

What the FDA Decides on November 27th, and What Comes Next

The FDA can approve BBP-418, approve it for a narrower group, or turn it down and ask for more. An approval would come with a label naming who it is for. The trial only enrolled people 12 and older, so an approval may not cover younger children at first. BridgeBio plans to start studies in children under 12 in the first half of 2027, and in 2 related conditions, LGMD2M/R13 and LGMD2U/R20.

BridgeBio says it is ready to launch as soon as the drug is approved. Trial Friend found no announced price or patient support program for BBP-418 as of October 18, 2026. Trial Friend's BBP-418 decision page will show the outcome, and the email alert on the LGMD page sends it the day it is announced.

LGMD2I/R9 Clinical Trials and Where to Find Support

ClinicalTrials.gov listed no treatment trials recruiting people with LGMD2I/R9 on October 18, 2026. The trials that exist are full or closed to new people.

• BBP-418's open-label extension (NCT07678775) continues treatment for people who finish FORTIFY, at 12 US sites.
• AskBio's AB-1003 gene therapy trial (NCT05230459) has enrolled 9 adults at 6 US sites and is no longer recruiting.
• Atamyo's ATA-100 gene therapy trial (NCT05224505) enrolled 6 people in Europe.
• A long-running University of Iowa study of people with dystroglycanopathies, including LGMD2I/R9 (NCT00313677), and a study building better ways to measure muscular dystrophy (NCT05989620) are recruiting. Neither gives a drug, and both follow people over time.

Joining a natural history study adds to the evidence future treatments are judged against. For everyday support, the LGMD2I Research Fund keeps a map of recommended medical centers, CureLGMD2i has a find-a-specialist list, The Speak Foundation runs LGMD Centers of Excellence and a patient network, and the Muscular Dystrophy Association runs care centers across the country.

Questions People Ask About BBP-418 and LGMD2I/R9

A sugar coat on one protein decides whether muscle cells hold up to everyday use. The FORTIFY results so far say that coat can be thickened with a drug taken by mouth, and that the muscles, lungs and maybe the heart notice. November 27th will show whether the FDA agrees, and the full 3-year trial will show how long it lasts.